Kewajiban jangka dawa marang ekuitas: COSCIENS Bio (CSCI)

This chart illustrating the price evolution of COSCIENS Biopharma Inc. (CSCI) demonstrates the price action of an asset whose operational resilience relies on logistics hubs and plants in Brazil. The indicator stands at 0.27, while strict FDA oversight and patent protection create significant barriers to entry for new players. However, a limited product pipeline and the licensing strategy carry risks characteristic of small biotech companies.

The assessment of the business's credit quality is based on an analysis of long-term leverage. This ratio correlates liabilities with a maturity of over one year to total equity, determining the degree of financial autonomy. For COSCIENS Biopharma Inc. (CSCI), this is critical when integrating assets following a merger and developing its endocrinology pipeline. The stability of equity directly impacts the company's resilience. The dynamics of the long-term financial dependency ratio reflect the current balance between debt capital and market value.